Journal: Revista da Sociedade Brasileira de Medicina Tropical

Article Title: Role of transforming growth factor-beta 1 and connective tissue growth factor levels in coronavirus disease-2019-related lung Injury: a prospective, observational, cohort study

doi: 10.1590/0037-8682-0615-2021

Figure Lengend Snippet: Study groups’ TGF-β1, CTGF, and other laboratory parameter results

Article Snippet: TGF-β1 and CTGF values were determined using the ELISA method with a Human TGF-β1 ELISA kit (Elabscience, Human TGF-β1: cat. E-EL-H0110, Texas, USA) and a human CTGF ELISA kit (Elabscience, Human CTGF: E-EL-H0828, Texas, USA) in accordance with the manufacturer’s recommendations.

Techniques:

Journal: Revista da Sociedade Brasileira de Medicina Tropical

Article Title: Role of transforming growth factor-beta 1 and connective tissue growth factor levels in coronavirus disease-2019-related lung Injury: a prospective, observational, cohort study

doi: 10.1590/0037-8682-0615-2021

Figure Lengend Snippet: Box-plot presentation of serum TGF-β1 and CTGF levels on day 7 of admission in Group 1 divided by severity of COVID-19 disease. *:p<0.001 (analysis of variance) two-way comparison of subgroups.

Article Snippet: TGF-β1 and CTGF values were determined using the ELISA method with a Human TGF-β1 ELISA kit (Elabscience, Human TGF-β1: cat. E-EL-H0110, Texas, USA) and a human CTGF ELISA kit (Elabscience, Human CTGF: E-EL-H0828, Texas, USA) in accordance with the manufacturer’s recommendations.

Techniques: Comparison

Journal: Revista da Sociedade Brasileira de Medicina Tropical

Article Title: Role of transforming growth factor-beta 1 and connective tissue growth factor levels in coronavirus disease-2019-related lung Injury: a prospective, observational, cohort study

doi: 10.1590/0037-8682-0615-2021

Figure Lengend Snippet: Changes in serum TGF-β1 and CTGF levels among disease severity subgroups.

Article Snippet: TGF-β1 and CTGF values were determined using the ELISA method with a Human TGF-β1 ELISA kit (Elabscience, Human TGF-β1: cat. E-EL-H0110, Texas, USA) and a human CTGF ELISA kit (Elabscience, Human CTGF: E-EL-H0828, Texas, USA) in accordance with the manufacturer’s recommendations.

Techniques:

Journal: Revista da Sociedade Brasileira de Medicina Tropical

Article Title: Role of transforming growth factor-beta 1 and connective tissue growth factor levels in coronavirus disease-2019-related lung Injury: a prospective, observational, cohort study

doi: 10.1590/0037-8682-0615-2021

Figure Lengend Snippet: Determination of the diagnostic sensitivity and specificity of serum TGF-β1 and CTGF levels on days 1 and 7 of admission in patients diagnosed with COVID-19 using ROC curve analysis. ROC: receiver-operating characteristic curve.

Article Snippet: TGF-β1 and CTGF values were determined using the ELISA method with a Human TGF-β1 ELISA kit (Elabscience, Human TGF-β1: cat. E-EL-H0110, Texas, USA) and a human CTGF ELISA kit (Elabscience, Human CTGF: E-EL-H0828, Texas, USA) in accordance with the manufacturer’s recommendations.

Techniques: Diagnostic Assay

Journal: Journal of pharmacological sciences

Article Title: Oligo-peptide I-C-F-6 inhibits hepatic stellate cell activation and ameliorates CCl 4 -induced liver fibrosis by suppressing NF-κB signaling and Wnt/β-catenin signaling.

doi: 10.1016/j.jphs.2018.01.003

Figure Lengend Snippet: Fig. 3. The effects of oligo-peptide I-C-F-6 on HSC activation markers and cytokine levels. (A) The immunohistochemistry of TGF-b1 and a-SMA. Magnification, 200. (B) The effects of oligo-peptide I-C-F-6 on TGF-b1 and a-SMA levels in vitro. The data are expressed as the means ± SD of three independent experiments. *P < 0.05, **P < 0.01 compared with 0 mg/ mL. (C) The effects of oligo-peptide I-C-F-6 on TGF-b1 and a-SMA levels in vivo. (DeG) Serum levels of CTGF, TNF-a, VEGF, TGF-b1. Data are expressed as means ± SD (n ¼ 6e8). #P < 0.05, ##P < 0.01 compared with the control group; *P < 0.05, **P < 0.01 compared with the CCl4 group.

Article Snippet: The MMP-2, MMP-9, TIPM-1, CTGF, TGF-b1, TNF-a, and VEGF ELISA kits were purchased from Cusabio Biotech (Wuhan, China).

Techniques: Activation Assay, Immunohistochemistry, In Vitro, In Vivo, Control

Journal: Cells

Article Title: CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy.

doi: 10.3390/cells9040952

Figure Lengend Snippet: Figure 1. CCN2 is expressed by FC1199 tumors. CCN2 was analyzed by immunohistochemistry (IHC) in healthy murine pancreas (A) and FC1199 orthotopic tumors (B,C). Black arrows: tubular structures of an adenocarcinoma with cellular atypia and differences in the thickness of the tubular wall. Red arrows: stromal areas. C is a higher magnification of the boxed area in B. CCN2 was expressed by both tumor cells (black arrows) and stroma cells (red arrow), scale bars: 50 µm. (D) CCN2 production by FC1199 cells in vitro. CCN2 in the cell lysate and conditioned media was measured by ELISA and expressed as µg/mL.

Article Snippet: CCN2 levels in conditioned media and cell lysate of FC1199 tumor cells were measured by ELISA (CSB-E07877m, Cusabio, Wuhan, China), according to the manufacturer’s instructions.

Techniques: Immunohistochemistry, In Vitro, Enzyme-linked Immunosorbent Assay

Journal: Cells

Article Title: CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy.

doi: 10.3390/cells9040952

Figure Lengend Snippet: Figure 3. Microenvironmental changes induced by BLR100 or BLR200 on PDAC tumors. Representative images and relative quantification of (A) fibrosis (polarized light microscopy analysis of Sirius red stained sections; scale bars, 25 µm), (B) necrosis (asterisks, H&E staining; scale bars, 200 µm) and (C) tumor vessels (CD31 IHC; scale bars, 200 µm) of control and peptide-treated FC1199 orthotopic tumors. N ≥6. One way ANOVA and Dunnett’s: * p < 0.05.

Article Snippet: CCN2 levels in conditioned media and cell lysate of FC1199 tumor cells were measured by ELISA (CSB-E07877m, Cusabio, Wuhan, China), according to the manufacturer’s instructions.

Techniques: Light Microscopy, Staining, Control

Journal: Cells

Article Title: CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy.

doi: 10.3390/cells9040952

Figure Lengend Snippet: Figure 5. Effect of BLR200 on gemcitabine distribution. Gemcitabine (A) and the dFdU metabolite (B) were measured by HPLC–MS analysis in plasma and tumors of mice bearing FC1199 orthotopic tumors, treated or not with BLR200. Data are the ratio between tumor (T) and plasma (P) concentration, 30 min and 1 h after gemcitabine administration (mean ± SEM, n = 4).

Article Snippet: CCN2 levels in conditioned media and cell lysate of FC1199 tumor cells were measured by ELISA (CSB-E07877m, Cusabio, Wuhan, China), according to the manufacturer’s instructions.

Techniques: Clinical Proteomics, Concentration Assay